Skip to main content
Top

Open Access 18-04-2024 | Cardiac Amyloidosis | Review

(Non)-Exertional Variables of Cardiopulmonary Exercise Testing in Heart Failure with and Without Cardiac Amyloidosis

Authors: Simon Wernhart, Lars Michel, Alexander Carpinteiro, Peter Luedike, Tienush Rassaf

Published in: Current Heart Failure Reports

Login to get access

Abstract

Purpose of Review

Cardiac amyloidosis (CA) constitutes an important etiology of heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF). Since patients with CA show early exhaustion, we aimed to investigate whether non-exertional variables of cardiopulmonary exercise testing (CPET) provide additional information in comparison to traditional peak oxygen consumption (VO2peak).

Recent Findings

We retrospectively investigated CPET variables of patients with HFpEF and HFmrEF with (n = 21) and without (n = 21, HF) CA at comparable age and ejection fraction. Exertional and non-exertional CPET variables as well as laboratory and echocardiographic markers were analyzed. The primary outcome was the difference in CPET variables between groups. The secondary outcome was rehospitalization in patients with CA during a follow-up of 24 months. Correlations between CPET, NTproBNP, and echocardiographic variables were calculated to detect patterns of discrimination between the groups. HF patients with CA were inferior to controls in most exertional and non-exertional CPET variables. Patients with CA were hospitalized more often (p = 0.002), and rehospitalization was associated with VE/VCO2 (p = 0.019), peak oxygen pulse (p = 0.042), the oxygen equivalent at the first ventilatory threshold (p = 0.003), circulatory (p = 0.024), and ventilatory power (p < .001), but not VO2peak (p = 0.127). Higher performance was correlated with lower E/e’ and NTproBNP as well as higher resting heart rate and stroke volume in CA.

Summary

Patients with CA displayed worse non-exertional CPET performance compared to non-CA HF patients, which was associated with rehospitalization. Differences between correlations of resting echocardiography and CPET variables between groups emphasize different properties of exercise physiology despite comparable ejection fraction.
Literature
2.•
go back to reference Paolillo S, Veglia F, Salvioni E, Corrà U, Piepoli M, Lagioia R, et al. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. Eur J Heart Fail. 2019;21(2):208–17. https://doi.org/10.1002/ejhf.1364. (This work illustrates the prognostic role of peak oxygen consumption and ventilatory efficiency in heart failure to assess hospitalization and cardiovascular death.).CrossRefPubMed Paolillo S, Veglia F, Salvioni E, Corrà U, Piepoli M, Lagioia R, et al. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. Eur J Heart Fail. 2019;21(2):208–17. https://​doi.​org/​10.​1002/​ejhf.​1364. (This work illustrates the prognostic role of peak oxygen consumption and ventilatory efficiency in heart failure to assess hospitalization and cardiovascular death.).CrossRefPubMed
3.•
go back to reference Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, et al. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):231–9. https://doi.org/10.1002/ejhf.2016. (The work illustrates the prognostic role of peak oxygen consumption and circulatory power in cardiac amyloidosis, which are tools to assess the risk of hospitalization and mortality.).CrossRefPubMed Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, et al. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):231–9. https://​doi.​org/​10.​1002/​ejhf.​2016. (The work illustrates the prognostic role of peak oxygen consumption and circulatory power in cardiac amyloidosis, which are tools to assess the risk of hospitalization and mortality.).CrossRefPubMed
8.
go back to reference Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29(1):230–45. https://doi.org/10.1093/eurjpc/zwab007.CrossRefPubMed Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29(1):230–45. https://​doi.​org/​10.​1093/​eurjpc/​zwab007.CrossRefPubMed
9.
go back to reference Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol. 2013;20(3):442–67. https://doi.org/10.1177/2047487312460484.CrossRefPubMed Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol. 2013;20(3):442–67. https://​doi.​org/​10.​1177/​2047487312460484​.CrossRefPubMed
19.
23.•
go back to reference Dalia T, Acharya P, Chan WC, Sauer AJ, Weidling R, Fritzlen J, et al. Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Card Fail. 2021;27(11):1285–9. https://doi.org/10.1016/j.cardfail.2021.06.022. (Low baseline peak oxygen consumption, oxygen pulse, circulatory power, and an exercise duration of less than 5.5 min had worse outcome for mortality, heart transplantation, and palliative inotrope therapy in patients with wild-type amyloidosis.).CrossRefPubMed Dalia T, Acharya P, Chan WC, Sauer AJ, Weidling R, Fritzlen J, et al. Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Card Fail. 2021;27(11):1285–9. https://​doi.​org/​10.​1016/​j.​cardfail.​2021.​06.​022. (Low baseline peak oxygen consumption, oxygen pulse, circulatory power, and an exercise duration of less than 5.5 min had worse outcome for mortality, heart transplantation, and palliative inotrope therapy in patients with wild-type amyloidosis.).CrossRefPubMed
37.
go back to reference Jondeau G, Katz SD, Zohman L, Goldberger M, Mccarthy M, Bourdarias JP, et al. Active skeletal muscle mass and cardiopulmonary reserve. Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation. 1992;86(5):1351–6. https://doi.org/10.1161/01.cir.86.5.1351. Jondeau G, Katz SD, Zohman L, Goldberger M, Mccarthy M, Bourdarias JP, et al. Active skeletal muscle mass and cardiopulmonary reserve. Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation. 1992;86(5):1351–6. https://​doi.​org/​10.​1161/​01.​cir.​86.​5.​1351.
Metadata
Title
(Non)-Exertional Variables of Cardiopulmonary Exercise Testing in Heart Failure with and Without Cardiac Amyloidosis
Authors
Simon Wernhart
Lars Michel
Alexander Carpinteiro
Peter Luedike
Tienush Rassaf
Publication date
18-04-2024
Publisher
Springer US
Published in
Current Heart Failure Reports
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-024-00661-1
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.